X-Chem and AstraZeneca: innovative technology partnership to identify lead molecules for drug discovery

Since 2012, we’ve been working with US-based X-Chem Inc. to improve the rate and quality of small molecule lead discovery, and expand the realm of 'druggable' targets.

X-Chem’s proprietary high-diversity library and ultra-efficient screening platform has been highly successful against historically challenging targets, including protein-protein interactions, epigenetic targets, the Ubiquitin family, antibacterial targets and G-protein coupled receptors. Our successful pilot programme focused on 20 targets. A year later, we expanded the collaboration to multiple therapy areas.



Related articles